Andrea Bagaméri

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 159 citations · Full text

Medicine, Gynecology, Oncology +16

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye, Laurence Gladieff, David M. O’Malley et al. · The Lancet · 2025 · 46 citations

Medicine, Oncology, Pharmacology +13

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Ignace Vergote, Keiichi Fujiwara, Elsa Kalbacher et al. · Annals of Oncology · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +13

Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study

Ignace Vergote, David Cibula, Matthew A. Powell et al. · International Journal of Gynecological Cancer · 2025 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

Ignace Vergote, Larry J. Copeland, Toon Van Gorp et al. · European Journal of Cancer · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17